(Albany, United States) As per DelveInsight’s assessment, globally, the Neuroendocrine Tumor pipeline constitutes 55+ key companies continuously working towards developing 60+ Neuroendocrine Tumor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

The Neuroendocrine Tumor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The Neuroendocrine Tumor pipeline report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, Neuroendocrine Tumor NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Neuroendocrine Tumor Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Key Takeaways from the Neuroendocrine Tumor Pipeline Report

• DelveInsight’s Neuroendocrine Tumor Pipeline analysis depicts a robust space with 55+ active players working to develop 60+ pipeline treatment therapies.
• The leading Neuroendocrine Tumor Companies are working in the market include Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radio, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe Inc, Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others
• Emerging Neuroendocrine Tumor Pipeline Therapies in the various stages of development include Somatostatin analog, AlphaMedix, 177Lu-DOTATATE 25.9 GBq activity, Lutetium-177 Octreotate, Gallium-68 DOTATOC, and others
• On June 2023, ITM Solucin GmbH has announced drug named 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) in the market of phase 3. The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
• On February 2023, University Hospital, Antwerp has announced drug named Somatostatin analog in the market of phase 4. The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive disease on first-line therapy with somatostatine analogues (SSA). Eligible patients will be divided into two substudies according to the second-line therapy of choice (peptide receptor radionuclide therapy (PRRT) or targeted therapy, at the discretion of the local investigator). Patients within each substudy will be randomised 1:1 between continuation or withdrawal from SSA at the start of second-line systemic therapy. Stratification will occur according to study site and according to the Ki67 value (below 10% (grade 1 and low grade 2) and equal to or above 10% (high grade 2)).

 

Neuroendocrine Tumor Overview

Neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells.

 

For further information, refer to the detailed Neuroendocrine Tumor Unmet Needs, click here for Neuroendocrine Tumor Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Neuroendocrine Tumor Emerging Drugs Profile

• ITM-11: ITM Solucin
• Alphamedix: RadioMedix
• BI 764532: Boehringer Ingelheim

 

Neuroendocrine Tumor Pipeline Therapeutics Assessment

There are approx. 55+ Neuroendocrine Tumor companies which are developing the therapies for Neuroendocrine Tumors. The Neuroendocrine Tumor companies which have their Neuroendocrine Tumors drug candidates in the most advanced stage, i.e. phase III include, ITM Solucin.

 

Request a sample and discover the recent advances in Neuroendocrine Tumor Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Neuroendocrine Tumor Drugs and Companies

• One injection of 68Ga-NODAGA-E[c(RGDyK)]2: Rigshospitalet, Denmark
• Gallium-68 DOTATOC: Northwell Health
• Lutetium-177 Octreotate: Ozmosis Research Inc.
• AlphaMedix: Radiomedix Inc
• Somatostatin Analog: Erasmus Medical Center

 

Neuroendocrine Tumor Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Neuroendocrine Tumor Therapeutics Market include-

Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radio, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe Inc, Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.

 

Dive deep into rich insights for drugs for Neuroendocrine Tumor Pipeline, click here for Neuroendocrine Tumor Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Scope of the Neuroendocrine Tumor Pipeline Report

• Coverage- Global
• Neuroendocrine Tumor Companies- Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radio, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe Inc, Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.
• Neuroendocrine Tumor Therapies- Somatostatin analog, AlphaMedix, 177Lu-DOTATATE 25.9 GBq activity, Lutetium-177 Octreotate, Gallium-68 DOTATOC, and others
• Neuroendocrine Tumor Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Neuroendocrine Tumor Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Table of Content

1. Introduction
2. Neuroendocrine Tumor Executive Summary
3. Neuroendocrine Tumors: Overview
4. Neuroendocrine Tumor Pipeline Therapeutics
5. Neuroendocrine Tumor Therapeutic Assessment
6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ITM-11: ITM Solucin
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Alphamedix: RadioMedix
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BI 764532: Boehringer Ingelheim
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Neuroendocrine Tumors Key Companies
18. Neuroendocrine Tumors Key Products
19. Neuroendocrine Tumors – Unmet Needs
20. Neuroendocrine Tumors – Market Drivers and Barriers
21. Neuroendocrine Tumors – Future Perspectives and Conclusion
22. Neuroendocrine Tumors Analyst Views
23. Neuroendocrine Tumors Key Companies
24. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment